Press Releases Category: View AllCorporateFinancialGenericsBrandedInternationalSterile Year: - Any -2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999 March 13, 2023 Summary ToggleEndo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis March 10, 2023 Summary ToggleEndo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules March 6, 2023 Summary ToggleENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS February 6, 2023 Summary ToggleEndo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease December 6, 2022 Summary ToggleEndo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes) November 9, 2022 Summary ToggleENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS October 27, 2022 Summary ToggleEndo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool October 7, 2022 Summary ToggleEndo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting October 5, 2022 Summary ToggleEndo Launches Unscripted Video Series With Real Dupuytren's Contracture Patients August 16, 2022 Summary ToggleEndo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation August 9, 2022 Summary ToggleENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS August 8, 2022 Summary TogglePaladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy July 15, 2022 Summary ToggleEndo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada July 1, 2022 Summary ToggleOpana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor July 1, 2022 Summary ToggleEndo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder June 13, 2022 Summary ToggleEndo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain June 9, 2022 Summary ToggleNational Survey of Over 1,500 Men Shows More Than Half Were Unsure of How to Improve Their Mental and Sexual Health; New Partnership Aims to Change That Through Education and Free Virtual Consultations May 5, 2022 Summary ToggleENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS May 5, 2022 Summary ToggleEndo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting May 2, 2022 Summary ToggleEndo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar April 20, 2022 Summary ToggleTennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo April 12, 2022 Summary ToggleEndo to Announce First-Quarter 2022 Financial Results March 28, 2022 Summary ToggleEndo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials March 3, 2022 Summary ToggleEndo Launches New Living Our Values Program to Recognize Outstanding Team Members March 2, 2022 Summary ToggleButt First: Endo Launches First Direct-to-Consumer Campaign for Qwo® (collagenase clostridium histolyticum-aaes) With 200+ Patient Events February 28, 2022 Summary ToggleENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS February 11, 2022 Summary ToggleEndo Comments on Default Judgment on Liability in Tennessee State Court February 7, 2022 Summary ToggleEndo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles January 25, 2022 Summary ToggleEndo to Announce Fourth Quarter and Full-Year 2021 Financial Results January 18, 2022 Summary ToggleEndo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims January 17, 2022 Summary TogglePaladin Labs Announces the Launch of Xydalba® (dalbavancin for injection) in Canada January 13, 2022 Summary ToggleEndo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism January 11, 2022 Summary ToggleEndo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development January 10, 2022 Summary ToggleEndo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold January 4, 2022 Summary ToggleEndo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution January 4, 2022 Summary ToggleEndo to Participate at J.P. Morgan 40th Annual Healthcare Conference December 23, 2021 Summary ToggleEndo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims December 23, 2021 Summary ToggleEndo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada December 15, 2021 Summary ToggleEndo Announces Favorable Final Ruling in California State Court Opioid Trial November 22, 2021 Summary ToggleEndo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting November 18, 2021 Summary ToggleEndo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection November 17, 2021 Summary ToggleEndo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines November 8, 2021 Summary ToggleEndo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care November 4, 2021 Summary ToggleEndo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance November 2, 2021 Summary ToggleCalifornia State Court Issues Tentative Ruling in Endo's Favor Following Opioid Trial October 25, 2021 Summary ToggleEndo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease October 22, 2021 Summary ToggleEndo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting October 5, 2021 Summary ToggleEndo to Announce Third Quarter 2021 Financial Results September 30, 2021 Summary ToggleEndo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting September 28, 2021 Summary ToggleEndo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims September 22, 2021 Summary ToggleEndo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States September 9, 2021 Summary ToggleEndo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation August 31, 2021 Summary ToggleEndo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation August 5, 2021 Summary ToggleEndo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance August 4, 2021 Summary ToggleEndo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case July 29, 2021 Summary ToggleEndo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting July 22, 2021 Summary ToggleEndo Announces Agreement in Principle to Settle Tennessee State Court Case July 15, 2021 Summary ToggleEndo Comments on Tennessee Appeals Court Orders June 24, 2021 Summary ToggleEndo to Announce Second Quarter 2021 Financial Results June 24, 2021 Summary ToggleEndo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021 June 11, 2021 Summary ToggleTennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo June 9, 2021 Summary TogglePaladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada May 12, 2021 Summary ToggleEndo to Participate at 2021 RBC Capital Markets Global Healthcare Virtual Conference May 6, 2021 Summary ToggleEndo Reports First-Quarter 2021 Financial Results And Updates 2021 Financial Guidance April 29, 2021 Summary ToggleEndo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021 April 27, 2021 Summary ToggleEndo Implements Board Succession Plan April 13, 2021 Summary ToggleEndo to Announce First Quarter 2021 Financial Results April 13, 2021 Summary ToggleEndo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery April 12, 2021 Summary ToggleADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada April 7, 2021 Summary ToggleEndo Comments on Entry of Default Liability Judgment in Tennessee State Court Case March 11, 2021 Summary ToggleEndo International plc Announces Pricing of Private Offering Of Senior Secured Notes March 11, 2021 Summary ToggleEndo International plc Announces Proposed Private Offering Of Senior Secured Notes March 4, 2021 Summary ToggleEndo International plc Commences Refinancing of its Existing Term Loan February 25, 2021 Summary ToggleEndo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance February 17, 2021 Summary ToggleEndo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference February 17, 2021 Summary ToggleEndo Appoints Jennifer M. Chao to Board of Directors January 26, 2021 Summary ToggleEndo to Announce Fourth-Quarter and Full-Year 2020 Financial Results January 5, 2021 Summary ToggleEndo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada January 5, 2021 Summary ToggleEndo Aesthetics Launches "Really Cellulite" Campaign January 4, 2021 Summary ToggleEndo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States December 18, 2020 Summary ToggleEndo to Participate at J.P. Morgan 39th Annual Healthcare Conference December 2, 2020 Summary ToggleEndo Completes Acquisition of BioSpecifics November 18, 2020 Summary ToggleEndo to Participate In Upcoming Investor Conferences November 18, 2020 Summary ToggleEndo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer November 5, 2020 Summary ToggleEndo Reports Third-Quarter 2020 Financial Results And Raises Full Year 2020 Financial Guidance November 5, 2020 Summary ToggleEndo Announces Strategic Actions to Further Position the Company for Long-Term Success November 2, 2020 Summary ToggleEndo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp. October 22, 2020 Summary ToggleEnvarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan October 19, 2020 Summary ToggleEndo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™ October 9, 2020 Summary ToggleEndo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS) October 7, 2020 Summary ToggleEndo to Announce Third Quarter 2020 Financial Results October 6, 2020 Summary ToggleEndo Releases First Environmental, Social and Governance Report October 1, 2020 Summary ToggleEndo Begins Shipment of Generic Kuvan® Tablets and Powder for Oral Solution (sapropterin dihydrochloride) September 25, 2020 Summary ToggleEndo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate September 24, 2020 Summary ToggleEndo to Present Qwo™ (collagenase clostridium histolyticum-aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS) September 8, 2020 Summary ToggleEndo to Participate at Citi 15th Annual BioPharma Virtual Conference August 21, 2020 Summary ToggleEndo International plc Announces The Expiration And Final Tender Results Of Its Previously Announced Tender Offer August 17, 2020 Summary ToggleEndo International plc Commences Tender Offer For Any And All Of Its Outstanding 5.75% Senior Notes Due 2022 August 5, 2020 Summary ToggleEndo Reports Second-Quarter 2020 Financial Results July 30, 2020 Summary ToggleEndo Announces Second Quarter 2020 Earnings Call Time Change
